Oral presentations
Discovery and qualification of multi-modality biomarkers for men starting long-term androgen deprivation therapy in the STAMPEDE clinical trial
Grist E, PCF 29th Annual Scientific Retreat Young Investigator Session 2022
LBA62 - Comparison of abiraterone acetate and prednisolone (AAP) or combination enzalutamide (ENZ) + AAP for metastatic hormone sensitive prostate cancer (mHSPC) starting androgen deprivation therapy (ADT): Overall survival (OS) results of 2 randomised phase III trials from the STAMPEDE protocol
Attard G, et al. ESMO 2022
1358O - Clinical qualification of transcriptome signatures for advanced prostate cancer (APC) starting androgen deprivation therapy (ADT) with or without abiraterone acetate and prednisolone (AAP): An ancillary study of the STAMPEDE AAP trial
Parry MA, et al. ESMO 2022
LBA4_PR - Abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men with high-risk non-metastatic (M0) prostate cancer (PCa): Combined analysis from two comparisons in the STAMPEDE platform protocol
Attard G, et al. ESMO 2021
Poster presentations
PCF SELECT targeted genome sequencing of Plasma DNA at progression on androgen deprivation therapy alone or with abraterone and enzalutamide: an ancillary study of the STAMPEDE trial
Leone G, et al. PCF 29th Annual Scientific Retreat 2022
High-sensitivity tracking of copy number alterations and single nucleotide variants in sequential plasma DNA collections from metastatic prostate cancer (mPC) patients
Trujillo B. and Vainauskas O., et al. EACR Liquid Biopsies 2022
5021 Copy number profiles of primary tumors for risk stratification of advanced prostate cancer: A biomarker study embedded in the multicenter STAMPEDE trial
Grist E, et al. ASCO 2021
https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.5021
P - 182 Tumour Infiltrating Lymphocytes assessment in the STAMPEDE cohort: association of brisk inflammation with high grade histology
Mendes L, et al. EACR-AACR-ASPIC Tum Microenvironment 2020
153 Multiregion expression profiling of prostate cancer from men randomized in the STAMPEDE trial: Stage I results of a multistage biomarker analysis
Grist E, et al. GU ASCO 2020
https://meetinglibrary.asco.org/record/183430/abstract
39 Copy number profiling of STAMPEDE trial patients to improve targeting of existing therapies for advanced hormone-sensitive prostate cancer
Grist E, et al. EACR Cancer Genomics Conference 2019
88 Whole genome expression analysis of diagnostic patient samples enrolled in the STAMPEDE clinical trial in advanced prostate cancer
Parry M, et al. EACR Cancer Genomics Conference 2019
29P - Implementing molecular characterisation of prostate cancer tissue from patients recruited to the multi-centre STAMPEDE trial: The STRATOSPHERE consortium
Grist E, et al. MAP. 2018
https://www.sciencedirect.com/science/article/pii/S0923753419323804